Welcome to our dedicated page for Quoin Pharmaceuticals news (Ticker: QNRX), a resource for investors and traders seeking the latest updates and insights on Quoin Pharmaceuticals stock.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) is a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, with a primary emphasis on severe genetic skin disorders and related conditions. The QNRX news feed on Stock Titan aggregates company press releases and market-moving updates that shed light on the progress of its clinical pipeline, regulatory interactions and financing activities.
Investors following QNRX news can see detailed updates on the development of the company’s lead asset, QRX003, a topical lotion in late-stage pivotal trials for Netherton Syndrome. Quoin regularly reports clinical data from investigator-led pediatric studies and pivotal programs, describing changes in skin condition, pruritus, sleep disturbance and use of concomitant medications in Netherton Syndrome patients. News items also cover initial positive data in Peeling Skin Syndrome and the potential versatility of QRX003 across multiple rare skin diseases.
Regulatory and designation milestones are another key component of Quoin’s news flow. The company has announced Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency for QRX003 in Netherton Syndrome, as well as Rare Pediatric Disease Designation in the United States. These updates provide context on potential market exclusivity and incentives that may affect the long-term outlook for the program.
Quoin’s news also highlights broader corporate developments, including private placement financings with healthcare-focused institutional investors, adoption of equity incentive plans, leadership changes such as the appointment of a new chief financial officer and shareholder meeting outcomes. In addition, the company issues regular communications about its NETHERTON NOW awareness campaign, releasing video episodes that feature patients, advocates and experts discussing the burden of Netherton Syndrome. For readers tracking QNRX, this news stream offers an ongoing view into clinical progress, regulatory events, capital formation and patient advocacy efforts related to Quoin’s rare disease focus.
Quoin Pharmaceuticals Ltd. announced a conference call for its third quarter 2022 business update, scheduled for November 10, 2022, at 10:00 a.m. ET. The call will follow the release of the company's financial results, which will be issued before the market opens on the same day. Investors can participate by calling either 1-877-270-2148 (domestic) or 1-412-902-6510 (international). The live and archived webcast will be accessible on the Quoin Pharmaceuticals website.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that it will report its third quarter 2022 financial results on November 10, 2022, before the market opens. Management will conduct a webcast and conference call at 8:30 a.m. ET on the same day to discuss the results and corporate updates. The dial-in numbers for the call are 1-877-270-2148 (domestic) and 1-412-902-6510 (international). Quoin focuses on developing therapeutics for rare and orphan diseases, with a pipeline targeting conditions like Netherton Syndrome and Epidermolysis Bullosa.
Quoin Pharmaceuticals Ltd. announces the initiation of a multicenter, open-label clinical trial assessing QRX003 topical lotion in patients with Netherton Syndrome currently receiving systemic biologic therapy. Conducted under an existing U.S. IND Application, the study will take place over 12 weeks, aiming to evaluate safety and efficacy. QRX003, a broad-spectrum serine protease inhibitor, targets skin kallikreins to enhance skin barrier function. There are currently no approved therapies for Netherton Syndrome, making this trial crucial for developing new treatment options.
Quoin Pharmaceuticals Ltd. has opened three clinical sites for its study of QRX003, a treatment for Netherton Syndrome, a rare skin condition. The double-blind, placebo-controlled trial began in June 2022 and aims to recruit patients across six sites in the US, with the remaining three expected to open soon. QRX003, if approved, could be the first treatment for this condition. Quoin plans to self-commercialize QRX003 and has formed marketing partnerships in 60 countries, enabling potential early access.
Quoin Pharmaceuticals Ltd. (QNRX) initiated a clinical trial for its lead product QRX003, aimed at treating Netherton Syndrome, and expanded its global partnerships to eight across 60 countries. The company closed a $16.8 million public offering, netting approximately $15 million. Despite a net loss of $2.7 million for Q2 2022, Quoin regained compliance with Nasdaq's listing requirements concerning stockholders’ equity and minimum bid price. Significant progress includes a research agreement with Queensland University of Technology for scleroderma treatment.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that it will report its second quarter 2022 financial results on August 18, 2022, prior to market open. Management will host a webcast and conference call at 8:30 a.m. ET the same day to discuss the results and provide a corporate update. The live call can be accessed via specific domestic and international dialing codes, and the archived webcast will be available on the company's website. Quoin focuses on developing therapeutic products for rare and orphan diseases, with a pipeline targeting multiple indications.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has closed its public offering of 11,050,000,000 ordinary shares, which equates to 2,210,000 American Depositary Shares (ADS) at $5.00 per ADS, alongside pre-funded warrants for 5,750,000,000 ordinary shares at $4.9999 each, generating $16.8 million in gross proceeds. The net proceeds will be utilized for general corporate purposes. The offering was facilitated by A.G.P./Alliance Global Partners, and the registration statement was approved by the SEC on August 5, 2022.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has priced a public offering of 2,210,000 American Depositary Shares (ADS) representing 11,050,000,000 ordinary shares at $5.00 per ADS, along with pre-funded warrants for 1,150,000 ADS at $4.9999 each. The total gross proceeds from the offering are expected to be $16.8 million, closing around August 9, 2022. Proceeds will be utilized for general corporate purposes. A.G.P./Alliance Global Partners is the sole placement agent for this offering, which follows an effective registration statement filed with the SEC.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that it received significant Scientific Advice from the European Medicines Agency (EMA) regarding its product, QRX003, for treating Netherton Syndrome. This guidance, delivered sooner than expected, will enhance the clinical development plan in both the US and Europe. Currently in a clinical study in the US, QRX003 aims to improve the skin barrier for Netherton patients. The company has also expanded its distribution network to 60 countries, emphasizing accessibility for patients post-approval.
Quoin Pharmaceuticals (NASDAQ: QNRX) has signed a License and Distribution Agreement with Endo Ventures, an affiliate of Endo International for its lead product, QRX003, aimed at treating Netherton Syndrome, in Canada. Paladin Labs, a subsidiary of Endo, will handle commercialization upon regulatory approval. This marks Quoin’s eighth agreement for QRX003, expanding its market presence to 60 countries. CEO Dr. Michael Myers expressed optimism about the partnership's potential to enhance patient access to Quoin's products once approved.
FAQ
What is the current stock price of Quoin Pharmaceuticals (QNRX)?
What is the market cap of Quoin Pharmaceuticals (QNRX)?
